Biomea Fusion, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Biomea Fusion, Inc. (BMEA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.05 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-24
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-09-30 was $12.59, a 42.91% increase year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-06-30 was $21.74, a 453.18% increase year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $5.46, a 11.20% increase year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-09-30 was $8.81, a 14.71% decline year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.05, a 89.54% decline from fiscal 2024.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $10.04, a 32.63% increase from fiscal 2023.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $7.57, a 44.19% increase from fiscal 2022.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $5.25, a 27.88% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.05 10-K · filed 2026-03-24 | |||
| 2024-12-31 | $10.04 10-K · filed 2026-03-24 | |||
| 2023-12-31 | $7.57 10-K · filed 2026-03-24 | |||
| 2023-09-30 | $12.59 10-Q · filed 2023-10-30 | $7.47 10-Q · filed 2023-10-30 | ||
| 2023-06-30 | $21.74 10-Q · filed 2023-07-31 | $6.44 10-Q · filed 2023-07-31 | ||
| 2023-03-31 | $5.46 10-Q · filed 2023-05-02 | |||
| 2022-12-31 | $5.25 10-K · filed 2025-03-31 | |||
| 2022-09-30 | $8.81 10-Q · filed 2023-10-30 | $4.91 10-Q · filed 2023-10-30 | ||
| 2022-06-30 | $3.93 10-Q · filed 2023-07-31 | $4.31 10-Q · filed 2023-07-31 | ||
| 2022-03-31 | $4.91 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | $7.28 10-K · filed 2024-03-28 | |||
| 2021-09-30 | $10.33 10-Q · filed 2022-11-07 | $7.26 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $13.27 10-Q · filed 2022-08-01 | $6.93 10-Q · filed 2022-08-01 | ||
| 2021-03-31 | $4.79 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |